[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"wet-age-related-macular-degeneration\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:wet-age-related-macular-degeneration":244},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,68,96,124,151,173,194,217],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":67},"100470574","phase-3-pivotal-2-study-of-rgx-314-gene-therapy-in-participants-with-namd-100470574",false,"NCT05407636","Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD","A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD","ASCENT","Inclusion Criteria:\n\n1. Age ≥ 50 years and ≤ 89 years\n2. An ETDRS BCVA letter score between ≤ 78 and ≥ 40 in the study eye\n3. Diagnosis of subfoveal choroidal neovascularization (CNV) secondary to AMD in the study eye previously treated with anti-VEGF\n4. Must be pseudophakic (at least 12 weeks postcataract surgery) in the study eye\n5. Willing and able to provide written, signed informed consent for this study\n6. Participants must have demonstrated a meaningful response to anti-VEGF therapy at study entry\n\nInclusion Criteria (Bilateral Treatment Substudy)\\*:\n\n1. An ETDRS BCVA letter score between ≤ 83 and ≥ 40 in both eyes\n2. Diagnosis of subfoveal choroidal neovascularization (CNV) secondary to AMD in both eyes\n3. Must be pseudophakic (at least 12 weeks postcataract surgery) in both eyes\n4. Willing and able to provide written, signed informed consent for this study\n5. Newcomers must have active disease in the study eye; crossover participants must have active disease in the eye not treated in the main study\n\nExclusion Criteria:\n\n1. CNV or macular edema in the study eye secondary to any causes other than AMD\n2. Subfoveal fibrosis or atrophy in the study eye\n3. Any condition in the investigator's opinion that could limit VA improvement in the study eye\n4. Advanced glaucoma or history of secondary glaucoma in the study eye\n5. Myocardial infarction, cerebrovascular accident, or transient ischemic attack within the past 6 months\n6. History of intraocular surgery in the study eye within 12 weeks prior to randomization\n7. History of intravitreal therapy in the study eye, such as intravitreal steroid injection or investigational medicinal product, other than an intravitreal therapy for AMD, in the 6 months prior to Week -6\n8. Prior treatment with gene therapy\n\nExclusion Criteria (Bilateral Treatment Substudy)\\*:\n\n1. CNV or macular edema in either eye secondary to any causes other than AMD\n2. Subfoveal fibrosis or atrophy in either eye\n3. Any condition in the investigator's opinion that could limit VA improvement in either eye\n4. Advanced glaucoma or history of secondary glaucoma in either eye\n5. Myocardial infarction, cerebrovascular accident, or transient ischemic attack within the past 6 months\n6. History of intraocular surgery in either eye within 12 weeks prior to randomization\n7. History of intravitreal therapy in the study eye, such as intravitreal steroid injection or investigational medicinal product, other than an intravitreal therapy for AMD, in the 6 months prior to Week -6.\n8. Prior treatment with gene therapy (\\*) For previously treated crossover participants, criteria apply to the eye not treated in the main study only.\n\nNote: Other inclusion\u002Fexclusion criteria apply","ALL","50 Years","89 Years",{"count":21,"type":22},714,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","ABBV-RGX-314 (also known as RGX-314 and surabgene lomparvovec (sura-vec)) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (VEGF) therapies have significantly changed the landscape for treatment of wet AMD, becoming the standard of care due to their ability to prevent progression of vision loss in the majority of patients. These therapies, however, require life-long intraocular injections, typically repeated every four to 12 weeks in frequency, to maintain efficacy. Due to the burden of treatment, patients often experience a decline in vision with reduced frequency of treatment over time. ABBV-RGX-314 is being developed as a potential one-time treatment for wet AMD.",[28,29,30,31,32,33],"AMD","nAMD","Wet Age-related Macular Degeneration","wAMD","WetAMD","CNV",[35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,28,54],"Age-Related Macular Degeneration","Neovascular Age-Related Macular Degeneration","Macular Degeneration","Wet Macular Degeneration","Choroidal Neovascularization","Retinal Degeneration","Retinal Diseases","Eye Diseases","Ranibizumab","Aflibercept","Angiogenesis Inhibitors","Angiogenesis Modulating Agents","Growth Substances","Physiological Effects of Drugs","Growth Inhibitors","Antineoplastic Agents","Gene Therapy","Anti-vascular endothelial grown factory therapy","Anti-VEGF therapy","wet AMD","RECRUITING","2026-04-15",{"date":58,"type":59},"2026-04-20","ACTUAL",{"date":61,"type":59},"2022-01-13",{"date":63,"type":22},"2027-11",{"name":65,"class":66},"AbbVie","INDUSTRY",181,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":95},"100401198","phase-2-mmp-9-inhibition-for-recalcitrant-wet-amd-100401198","NCT04504123","MMP-9 Inhibition for Recalcitrant Wet AMD","MMP-9 Inhibition for Recalcitrant Wet Age-Related Macular Degeneration (AMD)","Inclusion Criteria:\n\n* Wet age-related macular degeneration (wAMD);\n* Solely treated with anti-VEGF IVI for active CNV due to wAMD. However, enrolled patients can have other retinal pathologies such as diabetic retinopathy or vein occlusion for which they are not being treated with anti-VEGF IVI;\n* Must have persistent sub-retinal with or without intra-retinal fluid due to active CNV from wAMD despite receiving at least three consecutive injections with any anti-VEGF agent;\n* Must not have encountered previous side effects from tetracycline medications.\n\nExclusion Criteria - Ocular:\n\n* History of uveitis (including endophthalmitis) or presence of intraocular inflammation;\n* Presence of significant epiretinal membrane or macular hole causing distortion of macular anatomy;\n* Presence of media opacity preventing discerning of fluid on OCT;\n* Any prior ophthalmic surgery (including YAG or retinal laser) within the previous 3 months or anticipated need for any ophthalmic surgery (including cataract extraction) for 9 months following randomization;\n* History of peribulbar corticosteroid injection to the studied eye or the fellow eye within the past 6 months;\n* History of intravitreal triamcinolone acetonide injection to the studied eye within the past 4 months;\n* An ocular condition (other than AMD) is present in the studied eye that, in the opinion of the investigator, might alter visual acuity during the course of the study (e.g., retinal vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, and Irvine-Gass syndrome);\n* CNV due to causes other than wAMD;\n* Inability to follow up at the 6th and 9th months time points after recruitment;\n* Missing two or more consecutive injections during the six months treatment period;\n* Patient requiring imminent need for IVI anti-VEGF medication switch or another treatment intervention, such as photodynamic therapy, during the 9 months trial period;\n* Presence of fluid associated with geographic atrophy or disciform scar;\n* Any patient with sub-retinal and\u002For intra-retinal fluid that is not due to CNV (eg, overlying areas of geographic atrophy;\n* Any patient actively being actively treated for Irvine-Gass Syndrome.\n\nExclusion Criteria - Systemic:\n\n* Patient with and\u002For who developed an unstable medical status (e.g., glycemic control, blood pressure, cardiovascular disease, individuals who are unlikely or unable to complete the 9 months trial period) in the opinion of the investigator;\n* Significant renal disease (defined as a serum creatinine \\>2.5 mg\u002FdL);\n* Systolic blood pressure \\>180 mm Hg or diastolic blood pressure \\>110 mm Hg;\n* History of headaches associated with tetracycline therapy\n* History of pseudotumor cerebri;\n* History of tetracycline therapy within the past 6 months;\n* Pregnancy or patient intending to become pregnant within the 9 months of the trial period. For women of child-bearing potential, a pregnancy test will be performed;\n* Sexually active women of child-bearing potential not actively practicing birth control by using a medically accepted device or therapy (i.e., intrauterine device, hormonal contraceptive, or barrier device) during the study period (at least 24 months). This is important as doxycycline may interfere with the effectiveness of hormonal contraceptives. Hence, sexually active women of child-bearing potential who use a hormonal contraceptive will be required to use a second form of contraception to safeguard against contraceptive failure while participating in the study;\n* Known allergy\u002Fintolerance to doxycycline, tetracyclines, or any ingredient in the study drug or placebo;\n* Patients receiving phenytoin, barbiturates, carbamazepine, digoxin, or isotretinoin; patients with gastroparesis; patients with a history of gastrectomy, gastric bypass surgery, or otherwise deemed achlorhydric should all be excluded due to altered doxycycline pharmacokinetics and\u002For bioavailability;\n* Patients taking strontium, acitretin, or tretinoin should excluded due to the potential for serious interactions with doxycycline;\n* Patients with abnormal ALT or AST at baseline will be referred to their primary care physician for medical clearance for participation in this study.","99 Years",{"count":77,"type":22},50,[79],"PHASE2","Wet (or neovascular) form of age-related macular degeneration (wAMD) is the most common cause of blindness in the Western world. Currently, anti-vascular endothelial growth factor (VEGF) intravitreal injections (IVI) remain the standard-of-care treatment for wAMD. Previous studies show that about 90% of treated patients lose minimal visual function after 2 years of follow-up. There is still, a subset of 15% patients, incomplete responders, that do not improve and possibly worsen due to the persistence of sub-retinal fluid (with or without intra-retinal fluid) with chronic treatment.\n\nThe investigators plan to evaluate the effect of oral doxycycline versus placebo on the anatomic and functional outcomes in persistent sub-retinal eye fluid in neovascular wet age-related macular degeneration. This subset are incomplete or non-responders to current anti-VEGF intravitreal therapy.",[82,30],"Exudative Macular Degeneration",[84],"Active choroidal neovascularization (CNV)","2026-03-27",{"date":87,"type":59},"2026-04-02",{"date":89,"type":59},"2020-11-04",{"date":91,"type":22},"2027-03-01",{"name":93,"class":94},"University of Iowa","OTHER",1,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":103,"maxAge":75,"enrollmentInfo":104,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":107,"conditions":108,"keywords":109,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":95},"100618968","user-centric-study-of-patients-receptiveness-towards-the-web-based-automated-vision-impairment-gaze-tracking-analysis-systems-100618968","NCT07338513","User-centric Study of Patients' Receptiveness Towards the Web-based Automated Vision Impairment Gaze-tracking Analysis Systems","AVIGA-SURVEY","Inclusion Criteria:\n\n1. Subjects in the age group ≥ 55 to 99 years old.\n2. Both genders\n3. Able to understand verbal spoken instructions in British\u002FAmerican English, Chinese or Bahasa Melayu and demonstrate device functionality and implementation.\n4. Subjects undergoing treatment for Wet-AMD without any signs and symptoms of recurrence of active AMD (AMD recurrence: choroidal neovascularisation, intraretinal or subretinal fluid is present) with OCT lesion fluid volume more than 2mm2 or ILM height more than 300µm.\n5. Ability to comply with the study protocol, in the investigator's judgment.\n6. Subjects must be able to understand and provide informed consent. A signed informed consent form must be provided before any study assessments.\n\nExclusion Criteria:\n\n1. Unable to understand verbal spoken instructions and demonstrate device functionality and implementation.\n2. Unable to turn on and connect their computer to the AVIGA platform independently.\n3. Any ocular surgery in the previous 3 months, or vitrectomy in the previous 12 months\n4. Any history of macular pathology unrelated to AMD affecting vision or contributing to the presence of intraretinal or subretinal fluid in the study eye\n5. Any concurrent intraocular condition in the study eye that, in the opinion of the investigator, could either reduce the potential for visual improvement or require medical or surgical intervention during the study\n6. Any prior or concomitant treatment for CNV or vitreomacular-interface abnormalities in the study eye.\n7. History of idiopathic or autoimmune-associated uveitis in either eye\n8. Active ocular inflammation or suspected or active ocular or periocular infection in either eye.\n9. Severe cognitive impairment, comorbid conditions severely limiting participation (e.g., advanced hearing loss)","55 Years",{"count":105,"type":22},30,"OBSERVATIONAL","Age-Related Macular Degeneration (AMD) is the leading cause of central vision loss among older adults worldwide. Patients with AMD often require frequent monitoring of visual function and disease progression, typically through multiple follow-up visits involving optical coherence tomography (OCT), visual acuity testing (VA), and clinical consultations.\n\nWhile digital self-monitoring tools have emerged as promising solutions to reduce the burden of in-clinic visits, many elderly patients face challenges in engaging with these platforms due to visual impairment, limited digital literacy, and poorly optimised user interfaces. These barriers may reduce patient willingness to adopt such systems and undermine their long-term effectiveness.\n\nTo address this gap, the study team has developed the web-based AVIGA (Automated Vision Impairment Gaze-tracking Analysis) system, which is a portable, self-administered, home-based digital monitoring system designed to minimise cognitive load and maximise usability for elderly AMD patients. The platform integrates patient-centred design principles such as simplified navigation, optimised text, and multimodal feedback (visual and audio) to empower users to independently track their visual health.\n\nA prospective, single-site usability trial to evaluate the AVIGA platform using validated human factors measures: the System Usability Scale (SUS), the Technology Acceptance Model (TAM) will be conducted. By examining the relationship between usability, cognitive load, and perceived empowerment, this study aims to identify critical user interface and user experience (UI\u002FUX) design factors that influence willingness to adopt and sustain use of digital health tools among elderly AMD patients.",[35,30],[110,111,112,113],"user interface","user experience","Technology Acceptance Model","System Usability Scale","NOT_YET_RECRUITING","2026-01-05",{"date":117,"type":59},"2026-01-14",{"date":119,"type":22},"2026-01",{"date":121,"type":22},"2027-09",{"name":123,"class":94},"Tan Tock Seng Hospital",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":28,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":23,"phases":133,"briefSummary":134,"conditions":135,"keywords":136,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":150},"100589287","phase-3-pharmacogenomics-of-antivegf-in-patients-with-age-associated-macular-degeneration-amd-100589287","NCT06952452","Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)","Multicentre, Randomised, Double-blind, Parallel-group, Phase III Study to Evaluate the Genetic Polymorphism Influence in the Response to Ranibizumab and Bevacizumab Treatment in Patients With Age-Associated Macular Degeneration.","Inclusion Criteria:\n\n* Patients diagnosed with neovascular Age-related Macular Degeneration\n* Age of 50 years or older.\n* That at the discretion of the ophthalmologist has an indication of receiving treatment with an anti-VEGF agent as usual in clinical practice.\n* Without previous treatment in the eye under study (no previous treatment for AMD).\n\nExclusion Criteria:\n\n* Participate or have participated in another clinical trial with an experimental drug in the last 6 months.\n* Patients with other eye diseases, p. eg, advanced glaucoma or visually significant cataracts, which are likely to require surgery during the follow-up period in the eye under study.\n* Concomitant, ocular or systemic, administration of drugs up to 3 months before the treatment with another anti-VEGF in the contralateral eye.\n* High cardiovascular risk: poorly controlled arterial hypertension, history or risk of arterial thromboembolic events, history of stroke or acute myocardial infarction, anticoagulant treatment, proteinuria or major elective surgery within 3 months.\n* Ophthalmological risk with the intraocular injection (all intravitreal treatments): active or suspected ocular or periocular infection, severe blepharitis, history of endophthalmitis, history of retinal detachment, myopathy, glaucoma.\n* Hypersensitivity to the active substance or to the excipients.\n* Diabetic retinopathy documented.\n* Pregnant or nursing (lactating) women.\n\nPatients who meet elegibility criteria and decline participation due to treatment randomization, will participate in an observational follow-up, collecting saliva for the analysis of genetic polymorphisms and clinical data related to antiVEGF received out of the clinical trial and AV, OCT results and adverse events registered in medical records at 6m, 12m, 24m, 36m.",{"count":132,"type":22},630,[25],"This is a phase III, multicenter, randomized double-blinded clinical trial with two parallel groups (ranibizumab and bevacizumab) and an observational follow-up of patients who meet elegibility criteria and decline participation due to treatment randomization. It will be performed involving 630 eyes from patients with wet age-related macular degeneration (wAMD) diagnosis without another eye disease. This clinical trial compares the treatment response for 3 years, considering genetic variants already studied between the eyes treated with one of the first options of anti-VEGF used in patients with wAMD, (ranibizumab) and the most cost-effective anti-VEGF (bevacizumab; off-label use)",[30],[31,137,138,139,28,140],"antiVEGF","BVZ","RBZ","pharmacogenomics","2025-11-19",{"date":143,"type":59},"2025-11-20",{"date":145,"type":59},"2022-11-18",{"date":147,"type":22},"2026-07",{"name":149,"class":94},"Parc de Salut Mar",4,{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":23,"phases":160,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":4},"100606645","phase-1-evaluating-the-safety-and-preliminary-efficacy-of-exg202-gene-therapy-for-neovascular-amd-100606645","NCT07178249","Evaluating the Safety and Preliminary Efficacy of EXG202 Gene Therapy for Neovascular AMD","A Phase I\u002FII Clinical Study Evaluating the Safety and Preliminary Efficacy of EXG202 in Patients With Neovascular Age-related Macular Degeneration (nAMD)","Inclusion Criteria:\n\n1. Male or female, aged ≥50 years old;\n2. The study eye must be diagnosed of wAMD and current active lesions;\n3. Subjects have clear refractive media and sufficient pupil dilation at the time of screening to obtain high-quality retinal images for confirmation of diagnosis;\n4. Subjects (including male subjects) have no pregnancy plans during the screening period and the entire trial period and voluntarily take effective contraceptive measures and have no sperm or egg donation plans;\n5. Subjects are Voluntarily participate in this clinical trial, understand the research procedures and sign the informed consent form before screening; subjects have good compliance and are willing to abide by the research procedures.\n\nExclusion Criteria:\n\n1. The study eye has any eye disease other than wAMD that may affect central vision and\u002For macular detection ;\n2. The study eye has a history of retinal detachment or retinal detachment during the screening period;\n3. The study eye has MNV caused by reasons other than wAMD (such as diabetic retinopathy, pathological myopia, retinal vein occlusion, angioid streak disease, ocular histoplasmosis, trauma, etc.), and a history of macular pathology unrelated to wAMD;\n4. Any intraocular surgery is planned for the study eye during the study period;\n5. The study eye currently has retinal angiomatous proliferation (RAP), central serous chorioretinopathy or symptomatic vitreomacular traction syndrome;\n6. Presence of glaucoma or optic neuropathy that involves or compromises the central visual field of the study eye or presence of uncontrolled high intraocular pressure in the study eye；\n7. The fellow eye meets the definition of legal blindness；\n8. Hormone-induced increased intraocular pressure in any eye；\n9. Active infection in any eye this trial (such as those who cannot understand and comply with the trial requirements or are deemed unsuitable for safety reasons).",{"count":159,"type":22},60,[161,79],"PHASE1","VEGF inhibitors (anti-VEGF),such as aflibercept has been shown to be safe and effective for treating nAMD and have demonstrated improvement in vision. However, anti-VEGF therapy is administered frequently via intravitreal injection and can be a significant burden to the patients.\n\nEXG 202 is a recombinant adeno-associated virus (rAAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein. The long-term, stable delivery of this therapeutic protein following a 1 time gene therapy treatment for nAMD could potentially reduce the treatment burden of currently available therapies while maintaining vision with a favorable benefit.",[30],"2025-09-10",{"date":166,"type":59},"2025-09-17",{"date":168,"type":22},"2025-10-16",{"date":170,"type":22},"2032-12-30",{"name":172,"class":66},"Guangzhou Jiayin Biotech Ltd",{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":182,"conditions":183,"keywords":184,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":95},"100582146","a-long-term-follow-up-study-of-exg102-031-in-participants-with-wamd-100582146","NCT06859515","A Long-term Follow up Study of EXG102-031 in Participants With wAMD","A Long-term Follow-up Study to Evaluate the Injection of EXG102-031 Ophthalmic Injection in Participants With Wet Age-related Macular Degeneration (wAMD).","Inclusion Criteria:\n\n1. Previously received treatment with EXG102-031 in the study (EXG102-031-111);\n2. Paticipantes are informed consent and willingness to follow protocol procedures.\n\nExclusion Criteria:\n\n1\\. Paticipantes are unwilling or unable to participate in long-term follow-up",{"count":181,"type":22},42,"This is a long-term, safety and efficacy follow-up study of patients in the EXG102-031-111 gene therapy clinical trial for wAMD. Patients will complete visits from the parent study, and then into this long-term follow-up study for continuous safety monitoring for up to 5 years.",[30],[185,31],"AAV","2025-08-14",{"date":188,"type":59},"2025-08-15",{"date":190,"type":59},"2025-03-13",{"date":192,"type":22},"2030-12-01",{"name":172,"class":66},{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":23,"phases":202,"briefSummary":204,"conditions":205,"keywords":207,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":216},"100584373","early-phase-1-to-evaluate-the-safety-and-preliminary-efficacy-of-intravitreal-exg202-injection-in-patients-with-wet-neovascular-age-related-macular-degeneration-wamd-100584373","NCT06888492","To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)","An Open-label, Dose-escalation Study to Evaluate the Safety and Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)","Inclusion Criteria:\n\n1. Male or female, aged ≥50 years old;\n2. The study eye must meet the following criteria:\n\n   A. Diagnosed of wAMD and current active lesions; active, defined as the presence of any of the following lesions in the macular area upon OCT examination: a) intraretinal hemorrhage or fluid; b) subretinal fluid; c) subretinal hemorrhage; B. The BCVA score tested during screening using the ETDRS eye chart (see Appendix 3 for details) must be between 73-19 letters (including boundary values), (equivalent to Snellen visual acuity of 20\u002F40 to 20\u002F400);\n3. Clinically meaningful response to standard anti-VEGF therapy within 6 months before screening or during the lead-in period of screening.\n4. The subject has clear refractive media and sufficient pupil dilation at the time of screening to obtain high-quality retinal images for confirmation of diagnosis;\n5. Subjects (including male subjects) have no pregnancy plans during the screening period and the entire trial period and voluntarily take effective contraceptive measures and have no sperm or egg donation plans;\n6. Voluntarily participate in this clinical trial, understand the research procedures and sign the informed consent form before screening; have good compliance and are willing to abide by the research procedures.\n\nExclusion Criteria:\n\n1. The study eye has any eye disease other than wAMD that may affect central vision and\u002For macular detection (such as macular hole, macular epiretinal membrane, etc.);\n2. The study eye has a history of retinal detachment or retinal detachment during the screening period (such as rhegmatogenous retinal detachment, tractional retinal detachment, etc.);\n3. The study eye has MNV caused by reasons other than wAMD (such as diabetic retinopathy, pathological myopia, retinal vein occlusion, angioid streak disease, ocular histoplasmosis, trauma, etc.), and a history of macular pathology unrelated to wAMD;\n4. The study eye plans to undergo any intraocular surgery during the study period;",{"count":5,"type":22},[203],"EARLY_PHASE1","The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of intravitreal injection of EXG202 in subjects with neovascular age-related Macular Degeneration (nAMD).",[206,30],"Wet Age-related Macular Degeneration (wAMD)",[31,185],"2025-03-20",{"date":210,"type":59},"2025-03-21",{"date":212,"type":22},"2025-03-28",{"date":214,"type":22},"2026-04-30",{"name":172,"class":66},2,{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":23,"phases":226,"briefSummary":228,"conditions":229,"keywords":230,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":95},"100583355","phase-4-comparing-efficacy-of-8-week-and-12-week-faricimab-initial-follow-up-treatment-intervals-100583355","NCT06875245","Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals","Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals Following 4 Loading Doses - Prospective Randomised Study","Inclusion Criteria:\n\nActive treatment naïve CNV (Type 1, Type 2, or Type 3) in the macula including fovea diagnosed on OCT and OCTA\n\nBCVA between 70 to 35 ETDRS letters (approx. 20\u002F40 to 20\u002F200 Snellen equivalent) decrease in BCVA caused primarily by the CNV in the study eye\n\npresence of intra- or subretinal fluid or PED in the central 1 mm of the macula on the OCT\n\npatient capable of signing the informed consent\n\nExclusion Criteria:\n\nMyocardial Infarction or Stroke in the last 3 months\n\nPrevious or current conditions of the study eye:\n\n1. subretinal haemorrhage comprising more than 25% of the lesion in the study eye\n2. scar or fibrosis comprising more than 50% of the lesion in the study eye\n3. presence of retinal pigment epithelium (RPE) tears or ruptures in the central 1 mm of the macula in the study eye\n4. total lesion size more than 8 papillary diameters (PD) as per OCT and FP examination\n5. uncontrolled glaucoma in the study eye defined as IOP of more than 25 mmHg despite the antiglaucoma treatment\n6. idiopathic or autoimmune uveitis in the study eye\n7. other pathologies in the macula of the study eye unrelated to AMD which can be expected to influence the BCVA (e.g. macular hole, epiretinal membrane, etc.)\n\nk. significant opacities of the ocular media in the study eye including cataract, which can interfere with BCVA assessment or OCT examination\n\nn. diabetic retinopathy, diabetic macular edema or any other retinal vascular disease in the study eye\n\no. extraocular or periocular infection or inflammation (e.g. blepharitis, keratitis, conjunctivitis, scleritis, etc.) in any eye at the time of screening or baseline visit\n\np. any intraocular infection or inflammation in any eye during 12 weeks (84 days) before the screening visit\n\nq. allergy or hypersensitivity to any component contained in the study drug\n\nr. pregnant or breastfeeding women",{"count":225,"type":22},100,[227],"PHASE4","This is a prospective, randomized study that compares 8-week and 12-week follow-up intervals after the 4 monthly injections in the loading phase. Patients with active CNV confirmed on optical coherence tomography (OCT) and OCT angiography (OCTA) will be randomized into two groups and followed for 44 to 56 weeks.\n\nPatients in the first group will receive 4 injections of faricimab every 4 weeks, with the next visit and injection after 8 weeks, followed by a treat-and-extend regimen with a minimal interval of 8 weeks and a maximal interval of 16 weeks.\n\nPatients in the second group will also receive 4 loading doses with the next visit after an extended 12-week interval. Following treatment, patients in this group will be on the same treat-and-extend regimen as patients in the first group. The study will compare best corrected visual acuity (BCVA), central retinal thickness (CRT) on OCT, and the number of injections between both groups.",[30],[231,232,233,234],"retina","amd","faricimab","macula","2025-03-10",{"date":190,"type":59},{"date":238,"type":59},"2023-03-31",{"date":240,"type":22},"2026-04",{"name":242,"class":243},"Faculty Hospital Kralovske Vinohrady","OTHER_GOV","\"Wet\" Age-Related Macular Degeneration"]